10.1007/s40089-017-0208-0

Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases

HTML PDF
  • Anindita Chowdhury1,
  • Selvaraj Kunjiappan*2,
  • Theivendren Panneerselvam2,
  • Balasubramanian Somasundaram2,
  • Chiranjib Bhattacharjee1,
  1. Department of Chemical Engineering, Jadavpur University, Kolkata, West Bengal, 700032, IN
  2. Sir CV Raman-KS Krishnan International Research Center, Kalasalingam University, Krishnankoil, Tamil Nadu, 626126, IN
Cover Image

Published in Issue 2017-04-28

How to Cite

Chowdhury, A., Kunjiappan, S., Panneerselvam, T., Somasundaram, B., & Bhattacharjee, C. (2017). Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases. International Nano Letters, 7(2 (June 2017). https://doi.org/10.1007/s40089-017-0208-0
Crossref
Scopus
Google Scholar
Europe PMC

HTML views: 35

PDF views: 131

Abstract

Abstract Degenerative diseases are results of deterioration of cells and tissues with aging either by unhealthy lifestyle or normal senescence. The degenerative disease likely affects central nervous system and cardiovascular system to a great extent. Certain medications and therapies have emerged for the treatment of degenerative diseases, but in most cases bearing with poor solubility, lower bioavailability, drug resistance, and incapability to cross the blood–brain barrier (BBB). Hence, it has to be overcome with conventional treatment system; in this connection, nanotechnology has gained a great deal of interest in recent years. Moreover, nanotechnology and nanocarrier-based approach drug delivery system could revolutionize the treatment of degenerative diseases by faster absorption of drug, targeted interaction at specific site, and its release in a controlled manner into human body with minimal side effects. The core objective of this review is to customize and formulate therapeutically active molecules with specific site of action and without affecting other organs and tissues to obtain effective result in the improvement of quality of health. In addition, the review provides a concise insight into the recent developments and applications of nanotech and nanocarrier-based drug delivery for the treatment of various degenerative diseases.

Keywords

  • Degenerative diseases,
  • Nanotechnology,
  • Nanocarrier,
  • Biocompatibility,
  • Drug delivery,
  • Drug resistance,
  • Drug development,
  • Bioavailability,
  • Blood–brain barrier
HTML PDF

References

  1. Murray and Lopez (1994) Global and regional cause-of-death patterns in 1990 72(3)
  2. Finkel and Holbrook (2000) Oxidants, oxidative stress and the biology of ageing 408(6809) (pp. 239-247) https://doi.org/10.1038/35041687
  3. Cui, H., Kong, Y., Zhang, H.: Oxidative stress, mitochondrial dysfunction, and aging. J. Signal Trans. (2012)
  4. Uttara et al. (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options 7(1) (pp. 65-74) https://doi.org/10.2174/157015909787602823
  5. Alam, Q., ZubairAlam, M., Karim, S., H Gan, S., A Kamal, M., Jiman-Fatani, A., A Damanhouri, G., M Abuzenadah, A., G Chaudhary, A., Haque, A.: A nanotechnological approach to the management of Alzheimer disease and type 2 diabetes. CNS and Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)
  6. 13
  7. (3), 478–486 (2014)
  8. Oesterling et al. (2014) Nanocarrier-based approaches for treatment and detection of Alzheimer’s disease 14(1) (pp. 137-156) https://doi.org/10.1166/jnn.2014.8906
  9. Suri et al. (2007) Nanotechnology-based drug delivery systems 2(1) https://doi.org/10.1186/1745-6673-2-16
  10. Davis et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles 464(7291) (pp. 1067-1070) https://doi.org/10.1038/nature08956
  11. Hrkach, J., Von Hoff, D., Ali, M.M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A.: Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine
  12. 4
  13. (128), 128ra139–128ra139 (2012)
  14. Al-Quadeib et al. (2015) Stealth Amphotericin B nanoparticles for oral drug delivery: in vitro optimization 23(3) (pp. 290-302) https://doi.org/10.1016/j.jsps.2014.11.004
  15. Avgoustakis et al. (2002) PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties 79(1) (pp. 123-135) https://doi.org/10.1016/S0168-3659(01)00530-2
  16. Li et al. (2013) A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel 34(11) (pp. 2834-2842) https://doi.org/10.1016/j.biomaterials.2013.01.013
  17. Masood et al. (2013) Encapsulation of Ellipticine in poly-(3-hydroxybutyrate-co-3-hydroxyvalerate) based nanoparticles and its in vitro application 33(3) (pp. 1054-1060) https://doi.org/10.1016/j.msec.2012.11.025
  18. Jain et al. (2013) Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity 10(9) (pp. 3459-3474) https://doi.org/10.1021/mp400311j
  19. Khuroo et al. (2014) Topotecan-tamoxifen duple PLGA polymeric nanoparticles: investigation of in vitro, in vivo and cellular uptake potential 473(1) (pp. 384-394) https://doi.org/10.1016/j.ijpharm.2014.07.022
  20. Suseela et al. (2015) Formulation, characterization and pharmacokinetic evaluation of naringenin-loaded gastroretentive mucoadhesive polymeric nanosystem for oral drug delivery 5(2) (pp. 107-114)
  21. Salehi et al. (2013) Curcumin loaded NIPAAM/VP/PEG-A nanoparticles: physicochemical and chemopreventive properties 24(5) (pp. 574-588) https://doi.org/10.1080/09205063.2012.700111
  22. Avachat et al. (2014) Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles 11(3) (pp. 359-370) https://doi.org/10.2174/15672018113109990050
  23. Greish et al. (2004) SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours 97(2) (pp. 219-230) https://doi.org/10.1016/j.jconrel.2004.03.027
  24. Tsuji, A., Hamaguchi, T., Yamaguchi, K., Takeda, K., Uetake, H., Esaki, T., Amagai, K., Sugimoto, N., Baba, H., Kimura, M.: A phase II study of NK012, a polymeric micelle formulation of SN-38, in colorectal cancer patients who had received prior oxaliplatin-based regimen. In: ASCO Annual Meeting Proceedings. p. 3527 (2015)
  25. Uchino et al. (2005) Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats 93(6) (pp. 678-687) https://doi.org/10.1038/sj.bjc.6602772
  26. Musumeci et al. (2006) PLA/PLGA nanoparticles for sustained release of docetaxel 325(1) (pp. 172-179) https://doi.org/10.1016/j.ijpharm.2006.06.023
  27. Dignam et al. (2007) Daunomycin binding to detergent micelles: a model system for evaluating the hydrophobic contribution to drug-DNA interactions 111(39) (pp. 11576-11584) https://doi.org/10.1021/jp066877n
  28. Yang et al. (2011) Novel free paclitaxel-loaded poly (l-β-glutamylglutamine)-paclitaxel nanoparticles (pp. 85-91)
  29. Veronese et al. (2005) PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity 16(4) (pp. 775-784) https://doi.org/10.1021/bc040241m
  30. Singer, J.W., Baker, B., de Vries, P., Kumar, A., Shaffer, S., Vawter, E., Bolton, M., Garzone, P.: Poly-(l)-glutamic acid-paclitaxel (CT-2103)[XYOTAX], a biodegradable polymeric drug conjugate. In: Polymer drugs in the clinical stage. pp. 81–99. Springer (2004)
  31. Lodha et al. (2012) Synthesis of mesoporous silica nanoparticles and drug loading of poorly water soluble drug cyclosporin A 4(Suppl 1) https://doi.org/10.4103/0975-7406.94153
  32. Hom et al. (2010) Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells 6(11) (pp. 1185-1190) https://doi.org/10.1002/smll.200901966
  33. Atabaev et al. (2014) Highly mesoporous silica nanoparticles for potential drug delivery applications 4(03) https://doi.org/10.1142/S1793984414410037
  34. Quan et al. (2015) Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery 13(1) https://doi.org/10.1186/s12951-015-0068-6
  35. Hsiao et al. (2012) Design and characterization of a novel amphiphilic chitosan nanocapsule-based thermo-gelling biogel with sustained in vivo release of the hydrophilic anti-epilepsy drug ethosuximide 161(3) (pp. 942-948) https://doi.org/10.1016/j.jconrel.2012.05.038
  36. Tummala et al. (2015) Formulation and characterization of 5-fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer 23(3) (pp. 308-314) https://doi.org/10.1016/j.jsps.2014.11.010
  37. Amorim, C.d.M., Couto, A.l.G., Netz, D.J.A., de Freitas, R.A., Bresolin, T.M.B.: Antioxidant idebenone-loaded nanoparticles based on chitosan and
  38. N
  39. -carboxymethylchitosan. Nanomedicine: Nanotechnology, Biology and Medicine
  40. 6
  41. (6), 745–752 (2010)
  42. Xu et al. (2011) Targeted albumin-based nanoparticles for delivery of amphipathic drugs 22(5) (pp. 870-878) https://doi.org/10.1021/bc1002295
  43. Wong and Sumiran (2014) Oral calcium pectinate insulin nanoparticles: influences of alginate, sodium chloride and Tween 80 on their blood glucose lowering performance 66(5) (pp. 646-657) https://doi.org/10.1111/jphp.12192
  44. Das et al. (2011) Nanotechnology in oncology: characterization and in vitro release kinetics of cisplatin-loaded albumin nanoparticles: Implications in anticancer drug delivery 43(4) https://doi.org/10.4103/0253-7613.83111
  45. Xiao, Y., Liu, Y., Yang, S., Zhang, B., Wang, T., Jiang, D., Zhang, J., Yu, D., Zhang, N.: Sorafenib and Gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment. Colloids and Surfaces B: Biointerfaces (2016)
  46. Numico et al. (2002) Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial 35(1) (pp. 59-64) https://doi.org/10.1016/S0169-5002(01)00269-0
  47. Kunjiappan et al. (2014) A green chemistry approach for the synthesis and characterization of bioactive gold nanoparticles using Azolla microphylla methanol extract 8(2) (pp. 123-135) https://doi.org/10.1007/s11706-014-0246-8
  48. Narayani and Rao (1996) Biodegradable microspheres using two different gelatin drug conjugates for the controlled delivery of methotrexate 128(1) (pp. 261-268) https://doi.org/10.1016/0378-5173(95)04323-3
  49. Chowdhury et al. (2014) Green synthesis and characterization of biocompatible silver nanoparticles using Brassica oleracea L. leaf extract 6(4) (pp. 6166-6174)
  50. Dugan et al. (1997) Carboxyfullerenes as neuroprotective agents 94(17) (pp. 9434-9439) https://doi.org/10.1073/pnas.94.17.9434
  51. Alibolandi et al. (2016) Dextran-b-poly (lactide-co-glycolide) polymersome for oral delivery of insulin: in vitro and in vivo evaluation (pp. 58-70) https://doi.org/10.1016/j.jconrel.2016.02.031
  52. Zhang et al. (2016) Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor 12(5) (pp. 1279-1290) https://doi.org/10.1016/j.nano.2015.12.383
  53. Uchegbu et al. (1996) The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models 3(5) (pp. 399-409) https://doi.org/10.3109/10611869608996831
  54. Rogerson et al. (1988) The distribution of doxorubicin in mice following administration in niosomes 40(5) (pp. 337-342) https://doi.org/10.1111/j.2042-7158.1988.tb05263.x
  55. Liu et al. (2008) Drug delivery with carbon nanotubes for in vivo cancer treatment 68(16) (pp. 6652-6660) https://doi.org/10.1158/0008-5472.CAN-08-1468
  56. Ferrari (2005) Cancer nanotechnology: opportunities and challenges 5(3) (pp. 161-171) https://doi.org/10.1038/nrc1566
  57. Thakor and Gambhir (2013) Nanooncology: the future of cancer diagnosis and therapy 63(6) (pp. 395-418) https://doi.org/10.3322/caac.21199
  58. Ochekpe, N.A., Olorunfemi, P.O., Ngwuluka, N.C.: Nanotechnology and drug delivery part 1: background and applications. Tropical Journal of Pharmaceutical Research
  59. 8
  60. (3) (2009)
  61. Singh and Lillard (2009) Nanoparticle-based targeted drug delivery 86(3) (pp. 215-223) https://doi.org/10.1016/j.yexmp.2008.12.004
  62. Wilson et al. (2008) Targeted delivery of tacrine into the brain with polysorbate 80-coated poly (n-butylcyanoacrylate) nanoparticles 70(1) (pp. 75-84) https://doi.org/10.1016/j.ejpb.2008.03.009
  63. Wilson et al. (2008) Poly (n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease (pp. 159-168) https://doi.org/10.1016/j.brainres.2008.01.039
  64. Lazar et al. (2013) Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease 9(5) (pp. 712-721) https://doi.org/10.1016/j.nano.2012.11.004
  65. Huang and El-Sayed (2010) Gold nanoparticles: optical properties and implementations in cancer diagnosis and photothermal therapy 1(1) (pp. 13-28) https://doi.org/10.1016/j.jare.2010.02.002
  66. Arvizo et al. (2012) Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future 41(7) (pp. 2943-2970) https://doi.org/10.1039/c2cs15355f
  67. Thakkar et al. (2010) Biological synthesis of metallic nanoparticles 6(2) (pp. 257-262) https://doi.org/10.1016/j.nano.2009.07.002
  68. Elvira Nuez-Anita et al. (2014) Toxicology of antimicrobial nanoparticles for prosthetic devices (pp. 3999-4006)
  69. Lokina and Narayanan (2013) Antimicrobial and anticancer activity of gold nanoparticles synthesized from grapes fruit extract 2(S1) (pp. S105-S110)
  70. Yeo et al. (2003) Preparation of nanocomposite fibers for permanent antibacterial effect 38(10) (pp. 2143-2147) https://doi.org/10.1023/A:1023767828656
  71. Zhang et al. (2004) Sonochemical synthesis of colloidal silver catalysts for reduction of complexing silver in DTR system 266(1) (pp. 49-54) https://doi.org/10.1016/j.apcata.2004.01.025
  72. Zhang et al. (2006) Preparation of silver nanoparticles in water-in-oil AOT reverse micelles 302(1) (pp. 370-373) https://doi.org/10.1016/j.jcis.2006.06.035
  73. Chimentao et al. (2004) Different morphologies of silver nanoparticles as catalysts for the selective oxidation of styrene in the gas phase (pp. 846-847) https://doi.org/10.1039/B400762J
  74. He et al. (2004) Synthesis of size controlled Ag nanoparticles 221(1) (pp. 121-126) https://doi.org/10.1016/j.molcata.2004.06.025
  75. Yu (2007) Formation of colloidal silver nanoparticles stabilized by Na-poly (γ-glutamic acid)-silver nitrate complex via chemical reduction process 59(2) (pp. 171-178) https://doi.org/10.1016/j.colsurfb.2007.05.007
  76. Liu and Lin (2004) New pathway for the synthesis of ultrafine silver nanoparticles from bulk silver substrates in aqueous solutions by sonoelectrochemical methods 6(11) (pp. 1163-1168) https://doi.org/10.1016/j.elecom.2004.09.010
  77. Mallick et al. (2005) Self-assembly of silver nanoparticles in a polymer solvent: formation of a nanochain through nanoscale soldering 90(2) (pp. 221-224) https://doi.org/10.1016/j.matchemphys.2004.10.030
  78. Khomutov and Gubin (2002) Interfacial synthesis of noble metal nanoparticles 22(2) (pp. 141-146) https://doi.org/10.1016/S0928-4931(02)00162-5
  79. Oliveira et al. (2005) Influence of synthetic parameters on the size, structure, and stability of dodecanethiol-stabilized silver nanoparticles 292(2) (pp. 429-435) https://doi.org/10.1016/j.jcis.2005.05.068
  80. Egorova and Revina (2000) Synthesis of metallic nanoparticles in reverse micelles in the presence of quercetin 168(1) (pp. 87-96) https://doi.org/10.1016/S0927-7757(99)00513-0
  81. Song and Kim (2009) Rapid biological synthesis of silver nanoparticles using plant leaf extracts 32(1) (pp. 79-84) https://doi.org/10.1007/s00449-008-0224-6
  82. Nune et al. (2009) Green nanotechnology from tea: phytochemicals in tea as building blocks for production of biocompatible gold nanoparticles 19(19) (pp. 2912-2920) https://doi.org/10.1039/b822015h
  83. Giljohann et al. (2010) Gold nanoparticles for biology and medicine 49(19) (pp. 3280-3294) https://doi.org/10.1002/anie.200904359
  84. Das, S.K., Das, A.R., Guha, A.K.: Synthesis of gold nanoparticles: a green chemical approach. In: International conference on soft system ICSS-2008, Kolkata, India, pp. 3–15 (2008)
  85. Sperling et al. (2008) Biological applications of gold nanoparticles 37(9) (pp. 1896-1908) https://doi.org/10.1039/b712170a
  86. Chen et al. (2012) Effects of nanogold on the alleviation of carbon tetrachloride-induced hepatic injury in rats 55(5) (pp. 331-336)
  87. Mukherjee et al. (2005) Antiangiogenic properties of gold nanoparticles 11(9) (pp. 3530-3534) https://doi.org/10.1158/1078-0432.CCR-04-2482
  88. Gao et al. (2011) Effect of gold nanoparticles on glutathione depletion-induced hydrogen peroxide generation and apoptosis in HL7702 cells 205(1) (pp. 86-95) https://doi.org/10.1016/j.toxlet.2011.05.1018
  89. Ghosh et al. (2013) A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells 34(3) (pp. 807-816) https://doi.org/10.1016/j.biomaterials.2012.10.023
  90. Markman et al. (2013) Nanomedicine therapeutic approaches to overcome cancer drug resistance 65(13) (pp. 1866-1879) https://doi.org/10.1016/j.addr.2013.09.019
  91. Webster et al. (2013) Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics 84(1) (pp. 1-20) https://doi.org/10.1016/j.ejpb.2012.12.009
  92. Visaria et al. (2006) Enhancement of tumor thermal therapy using gold nanoparticle assisted tumor necrosis factor-α delivery 5(4) (pp. 1014-1020) https://doi.org/10.1158/1535-7163.MCT-05-0381
  93. Lee, J.-M., Yoon, T.-J., Cho, Y.-S.: Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed Res. Int.
  94. 2013
  95. (2013)
  96. Bonoiu et al. (2009) Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons 106(14) (pp. 5546-5550) https://doi.org/10.1073/pnas.0901715106
  97. Cognet et al. (2003) Single metallic nanoparticle imaging for protein detection in cells 100(20) (pp. 11350-11355) https://doi.org/10.1073/pnas.1534635100
  98. O’Neal et al. (2004) Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles 209(2) (pp. 171-176) https://doi.org/10.1016/j.canlet.2004.02.004
  99. Huang et al. (2007) Biosynthesis of silver and gold nanoparticles by novel sundried Cinnamomum camphora leaf 18(10) https://doi.org/10.1088/0957-4484/18/10/105104
  100. Lee et al. (2011) Green synthesis of phytochemical-stabilized Au nanoparticles under ambient conditions and their biocompatibility and antioxidative activity 21(35) (pp. 13316-13326) https://doi.org/10.1039/c1jm11592h
  101. Jain et al. (2009) Synthesis of plant-mediated silver nanoparticles using papaya fruit extract and evaluation of their anti microbial activities 4(3) (pp. 557-563)
  102. Kim et al. (2007) Antimicrobial effects of silver nanoparticles 3(1) (pp. 95-101) https://doi.org/10.1016/j.nano.2006.12.001
  103. Nadworny et al. (2008) Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model 4(3) (pp. 241-251) https://doi.org/10.1016/j.nano.2008.04.006
  104. Rao, P.V., Nallappan, D., Madhavi, K., Rahman, S., Jun Wei, L., Gan, S.H.: Phytochemicals and Biogenic Metallic Nanoparticles as Anticancer Agents. Oxidative Medicine and Cellular Longevity
  105. 2016
  106. (2016)
  107. Ahamed et al. (2010) Silver nanoparticle applications and human health 411(23–24) (pp. 1841-1848) https://doi.org/10.1016/j.cca.2010.08.016
  108. Senyei et al. (1978) Magnetic guidance of drug carrying microspheres 49(6) (pp. 3578-3583) https://doi.org/10.1063/1.325219
  109. Widder et al. (1978) Magnetic microspheres: a model system for site specific drug delivery in vivo 158(2) (pp. 141-146) https://doi.org/10.3181/00379727-158-40158
  110. Grancharov et al. (2005) Bio-functionalization of monodisperse magnetic nanoparticles and their use as biomolecular labels in a magnetic tunnel junction based sensor 109(26) (pp. 13030-13035) https://doi.org/10.1021/jp051098c
  111. McBain et al. (2008) Magnetic nanoparticles for gene and drug delivery 3(2)
  112. Sun, X.: Mesoporous silica nanoparticles for applications in drug delivery and catalysis. Graduate Theses and Dissertations, Paper 12812. (2012)
  113. Tang et al. (2012) Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery 24(12) (pp. 1504-1534) https://doi.org/10.1002/adma.201104763
  114. Huh et al. (2003) Tuning of particle morphology and pore properties in mesoporous silicas with multiple organic functional groups (pp. 2364-2365) https://doi.org/10.1039/b306255d
  115. Guo et al. (2011) Hollow mesoporous silica nanoparticles for intracellular delivery of fluorescent dye 5(1) https://doi.org/10.1186/1752-153X-5-1
  116. Upadhyay, R.K.: Drug delivery systems, CNS protection, and the blood brain barrier. BioMed Res. Int.
  117. 2014
  118. (2014)
  119. Brooks (2008) Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective 4(1) https://doi.org/10.2147/NDT.S1660
  120. Trapani et al. (2011) Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery 419(1) (pp. 296-307) https://doi.org/10.1016/j.ijpharm.2011.07.036
  121. Yang et al. (2012) Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
  122. Shenoy and Amiji (2005) Poly (ethylene oxide)-modified poly (epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer 293(1) (pp. 261-270) https://doi.org/10.1016/j.ijpharm.2004.12.010
  123. Makeshwar and Wasankar (2013) Niosome: a novel drug delivery system 3(1) (pp. 16-20)
  124. Moghassemi and Hadjizadeh (2014) Nano-niosomes as nanoscale drug delivery systems: an illustrated review (pp. 22-36) https://doi.org/10.1016/j.jconrel.2014.04.015
  125. Junginger et al. (1991) Liposomes and niosomes: interactions with human skin 106(8) (pp. 45-50)
  126. Kumar, B., Dwivedi, C., Tiwari, S.P., Satapathy, T.: Int. J. Res. Pharmacol. Pharmacother. (2014)
  127. Liechty et al. (2010) Polymers for drug delivery systems https://doi.org/10.1146/annurev-chembioeng-073009-100847
  128. Yurkovetskiy and Fram (2009) XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer 61(13) (pp. 1193-1202) https://doi.org/10.1016/j.addr.2009.01.007
  129. Duncan (2006) Polymer conjugates as anticancer nanomedicines 6(9) (pp. 688-701) https://doi.org/10.1038/nrc1958
  130. Lee and Park (2011) Biodegradable polymer vesicles: design and performance as drug delivery carriers
  131. Ahmed et al. (2006) Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug 116(2) (pp. 150-158) https://doi.org/10.1016/j.jconrel.2006.07.012
  132. Li et al. (2007) Self-assembled Poly (butadiene)-b-poly (ethylene oxide) polymersomes as paclitaxel carriers 23(1) (pp. 278-285) https://doi.org/10.1002/bp060185z
  133. Chen et al. (2010) pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles 142(1) (pp. 40-46) https://doi.org/10.1016/j.jconrel.2009.09.023
  134. Madaan et al. (2014) Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues 6(3) https://doi.org/10.4103/0975-7406.130965
  135. Tomalia et al. (2002) A new class of polymers: starburst-dendritic macromolecules 34(5) (pp. 132-147)
  136. Dufes et al. (2005) Dendrimers in gene delivery 57(15) (pp. 2177-2202) https://doi.org/10.1016/j.addr.2005.09.017
  137. Kim et al. (2010) Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction 7(1) (pp. 49-62) https://doi.org/10.1517/17425240903380446
  138. Gaucher et al. (2005) Block copolymer micelles: preparation, characterization and application in drug delivery 109(1) (pp. 169-188) https://doi.org/10.1016/j.jconrel.2005.09.034
  139. Croy and Kwon (2006) Polymeric micelles for drug delivery 12(36) (pp. 4669-4684) https://doi.org/10.2174/138161206779026245
  140. Bangham, A.D., Horne, R.W.: Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol.
  141. 8
  142. (5), 660IN662–668IN610 (1964)
  143. Spuch, C., Navarro, C.: Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s Disease and Parkinson’s Disease). J. Drug Deliv.
  144. 2011
  145. (2011)
  146. Samad et al. (2007) Liposomal drug delivery systems: an update review 4(4) (pp. 297-305) https://doi.org/10.2174/156720107782151269
  147. Alexis, F., Pridgen, E.M., Langer, R., Farokhzad, O.C.: Nanoparticle technologies for cancer therapy. In: Drug delivery. pp. 55–86. Springer (2010)
  148. Bagalkot et al. (2015) Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals (pp. 243-255) https://doi.org/10.1016/j.jconrel.2015.09.027
  149. Ge et al. (2012) Protein-polymer hybrid nanoparticles for drug delivery 8(23) (pp. 3573-3578) https://doi.org/10.1002/smll.201200889
  150. Lohcharoenkal, W., Wang, L., Chen, Y.C., Rojanasakul, Y.: Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Research International
  151. 2014
  152. (2014)
  153. Elsadek and Kratz (2012) Impact of albumin on drug delivery-new applications on the horizon 157(1) (pp. 4-28) https://doi.org/10.1016/j.jconrel.2011.09.069
  154. Yousefpour and Chilkoti (2014) Co-opting biology to deliver drugs 111(9) (pp. 1699-1716) https://doi.org/10.1002/bit.25307
  155. Moghimi et al. (2001) Long-circulating and target-specific nanoparticles: theory to practice 53(2) (pp. 283-318)
  156. Tokuda (2003) Antibodies as molecular target-based therapy: trastuzumab 8(4) (pp. 224-229) https://doi.org/10.1007/s10147-003-0334-8
  157. Reddy (2000) Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs 34(7–8) (pp. 915-923) https://doi.org/10.1345/aph.10054
  158. Elzoghby et al. (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems 157(2) (pp. 168-182) https://doi.org/10.1016/j.jconrel.2011.07.031
  159. Young Yhee et al. (2015) Molecular imaging and targeted drug delivery using albumin-based nanoparticles 21(14) (pp. 1889-1898) https://doi.org/10.2174/1381612821666150302115809
  160. Kratz (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles 132(3) (pp. 171-183) https://doi.org/10.1016/j.jconrel.2008.05.010
  161. Elzoghby (2013) Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research 172(3) (pp. 1075-1091) https://doi.org/10.1016/j.jconrel.2013.09.019
  162. Chandy, T., Sharma, C.P.: Resorbable chitosan matrix-a promising biomaterial for the future. In: Biomedical Engineering Conference, 1995., Proceedings of the 1995 Fourteenth Southern 1995, pp. 282–285. IEEE
  163. Dhillon et al. (2013) Green synthesis approach: extraction of chitosan from fungus mycelia 33(4) (pp. 379-403) https://doi.org/10.3109/07388551.2012.717217
  164. Chaudhury and Das (2011) Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents 12(1) (pp. 10-20) https://doi.org/10.1208/s12249-010-9561-2
  165. Harris et al. (2011) Chitosan nanoparticles and microspheres for the encapsulation of natural antioxidants extracted from Ilex paraguariensis 84(2) (pp. 803-806) https://doi.org/10.1016/j.carbpol.2010.07.003
  166. Raffa, V., Vittorio, O., Riggio, C., Ciofani, G., Cuschieri, A.: Physical properties of carbon nanotubes for therapeutic applications. In: Carbon Nanotubes for Biomedical Applications. pp. 3–26. Springer, (2011)
  167. Zhang et al. (2011) The application of carbon nanotubes in target drug delivery systems for cancer therapies 6(1) (pp. 1-22)
  168. Ferluga et al. (2014) A potential anti-coagulant role of complement factor H 59(2) (pp. 188-193) https://doi.org/10.1016/j.molimm.2014.02.012
  169. Jiang et al. (2007) Advances and challenges of nanotechnology-based drug delivery systems 4(6) (pp. 621-633) https://doi.org/10.1517/17425247.4.6.621
  170. Chan, W.C.W.: Bio-applications of Nanoparticles, vol. 620. Springer Science and Business Media (2009)
  171. Bakry et al. (2007) Medicinal applications of fullerenes 2(4)
  172. Misra, R., Upadhyay, M., Mohanty, S.: Design considerations for chemotherapeutic drug nanocarriers. Pharmaceutica Analytica Acta
  173. 2014
  174. (2014)
  175. Liu et al. (2013) pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery 8(3) (pp. 159-167) https://doi.org/10.1016/j.ajps.2013.07.021
  176. Nguyen, K.T.: Targeted nanoparticles for cancer therapy: promises and challenges. J. Nanomed. Nanotechnol.
  177. 2011
  178. (2011)
  179. Cao et al. (2009) Reversible cell-specific drug delivery with aptamer-functionalized liposomes 48(35) (pp. 6494-6498) https://doi.org/10.1002/anie.200901452
  180. Muntimadugu et al. (2016) CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel (pp. 532-546) https://doi.org/10.1016/j.colsurfb.2016.03.075
  181. Nagesh et al. (2016) PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer (pp. 8-20) https://doi.org/10.1016/j.colsurfb.2016.03.071
  182. Di-Wen et al. (2016) Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers 500(1) (pp. 54-61) https://doi.org/10.1016/j.ijpharm.2015.12.066
  183. Xie et al. (2016) EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery (pp. 28-35) https://doi.org/10.1016/j.ejps.2015.12.014
  184. Singh et al. (2016) EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model 12(3) (pp. 589-600) https://doi.org/10.1016/j.nano.2015.11.010
  185. Danesh et al. (2015) Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles 489(1) (pp. 311-317) https://doi.org/10.1016/j.ijpharm.2015.04.072
  186. Chittasupho et al. (2014) Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles 88(2) (pp. 529-538) https://doi.org/10.1016/j.ejpb.2014.06.020
  187. Robinson et al. (2015) Drugs and drug delivery systems targeting amyloid-β in Alzheimer’s 2(3) (pp. 332-358) https://doi.org/10.3934/molsci.2015.3.332
  188. Pahnke et al. (2008) Clinico-pathologic function of cerebral ABC transporters implications for the pathogenesis of Alzheimer’s disease 5(4) https://doi.org/10.2174/156720508785132262
  189. Dinda and Pattnaik (2013) Nanobiotechnology-based drug delivery in brain targeting 14(15) (pp. 1264-1274) https://doi.org/10.2174/1389201015666140608143719
  190. Kwon et al. (2016) Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer’s disease 10(2) (pp. 2860-2870) https://doi.org/10.1021/acsnano.5b08045
  191. Matveyenko and Butler (2008) Relationship between β-cell mass and diabetes onset 10(s4) (pp. 23-31) https://doi.org/10.1111/j.1463-1326.2008.00939.x
  192. Gendelman et al. (2015) Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases 11(3) (pp. 751-767) https://doi.org/10.1016/j.nano.2014.12.014
  193. Lu et al. (2014) Chitosan-graft-polyethyleneimine/DNA nanoparticles as novel non-viral gene delivery vectors targeting osteoarthritis 9(1) https://doi.org/10.1371/journal.pone.0084703
  194. McDonagh, B.H.: Multifunctional nanoparticles for bioimaging (2015)
  195. Qian and Pollard (2010) Macrophage diversity enhances tumor progression and metastasis 141(1) (pp. 39-51) https://doi.org/10.1016/j.cell.2010.03.014
  196. Rocha and Libby (2009) Obesity, inflammation, and atherosclerosis 6(6) (pp. 399-409) https://doi.org/10.1038/nrcardio.2009.55
  197. De Luca and Olefsky (2008) Inflammation and insulin resistance 582(1) (pp. 97-105) https://doi.org/10.1016/j.febslet.2007.11.057
  198. Lameijer et al. (2013) Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease 13(6) (pp. 567-580) https://doi.org/10.1586/14737159.2013.819216
  199. Moghimi et al. (2012) Particulate systems for targeting of macrophages: basic and therapeutic concepts 4(5–6) (pp. 509-528) https://doi.org/10.1159/000339153
  200. Chellat et al. (2005) Therapeutic potential of nanoparticulate systems for macrophage targeting 26(35) (pp. 7260-7275) https://doi.org/10.1016/j.biomaterials.2005.05.044
  201. Shilakari Asthana, G., Asthana, A., Kohli, D.V., Vyas, S.P.: Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting. BioMed Res. Int.
  202. 2014
  203. (2014)
  204. Gao et al. (2013) Novel monodisperse PEGtide dendrons: design, fabrication, and evaluation of mannose receptor-mediated macrophage targeting 24(8) (pp. 1332-1344) https://doi.org/10.1021/bc400011v
  205. Yu et al. (2013) Macrophage-specific RNA interference targeting via click, mannosylated polymeric micelles 10(3) (pp. 975-987) https://doi.org/10.1021/mp300434e
  206. Zhu et al. (2013) Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles 10(9) (pp. 3525-3530) https://doi.org/10.1021/mp400216r
  207. Pruthi et al. (2012) Macrophages targeting of amphotericin B through mannosylated multiwalled carbon nanotubes 20(7) (pp. 593-604) https://doi.org/10.3109/1061186X.2012.697168
  208. Tiwari et al. (2011) Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres 12(3) (pp. 900-908) https://doi.org/10.1208/s12249-011-9654-6
  209. Wood et al. (2013) PKC-pseudosubstrate and catalytic activity are necessary for membrane delivery during IgG-mediated phagocytosis 94(1) (pp. 109-122) https://doi.org/10.1189/jlb.1212634
  210. Zhao et al. (2013) Preparation, macrophages targeting delivery and anti-inflammatory study of pentapeptide grafted nanostructured lipid carriers 450(1) (pp. 11-20) https://doi.org/10.1016/j.ijpharm.2013.04.030
  211. Jain and Amiji (2012) Tuftsin-modified alginate nanoparticles as a noncondensing macrophage-targeted DNA delivery system 13(4) (pp. 1074-1085) https://doi.org/10.1021/bm2017993
  212. Betageri et al. (1993) Fc-receptor-mediated targeting of antibody-bearing liposomes containing dideoxycytidine triphosphate to human monocyte/Macrophages 45(1) (pp. 48-53) https://doi.org/10.1111/j.2042-7158.1993.tb03678.x
  213. Gu et al. (2011) Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells 12(4) (pp. 1200-1208) https://doi.org/10.1208/s12249-011-9668-0
  214. Richman et al. (2013) Effective targeting of Aβ to macrophages by sonochemically prepared surface-modified protein microspheres 14(1) (pp. 110-116) https://doi.org/10.1021/bm301401b
  215. Kamat et al. (2010) Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages 21(11) (pp. 2128-2135) https://doi.org/10.1021/bc100354m
  216. Gaspar, R.r., Prat, V., Opperdoes, F.R., Roland, M.: Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm. Res.
  217. 9
  218. (6), 782–787 (1992)
  219. Aouadi et al. (2009) Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation 458(7242) (pp. 1180-1184) https://doi.org/10.1038/nature07774
  220. Huang et al. (2012) Relative contributions of dectin-1 and complement to immune responses to particulate β-glucans 189(1) (pp. 312-317) https://doi.org/10.4049/jimmunol.1200603
  221. Liby and Sporn (2012) Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease 64(4) (pp. 972-1003) https://doi.org/10.1124/pr.111.004846
  222. Chen et al. (2011) Inflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammation 32(30) (pp. 7651-7661) https://doi.org/10.1016/j.biomaterials.2011.06.030
  223. Sipkins et al. (2000) ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging 104(1) (pp. 1-9) https://doi.org/10.1016/S0165-5728(99)00248-9
  224. Weller et al. (2003) Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to intercellular adhesion molecule-1 108(2) (pp. 218-224) https://doi.org/10.1161/01.CIR.0000080287.74762.60
  225. Zhang et al. (2007) PLGA nanoparticle peptide conjugate effectively targets intercellular cell-adhesion molecule-1 19(1) (pp. 145-152) https://doi.org/10.1021/bc700227z
  226. Kelly et al. (2005) Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle 96(3) (pp. 327-336) https://doi.org/10.1161/01.RES.0000155722.17881.dd
  227. Voinea et al. (2005) Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells-a potential tool for specific drug delivery 22(11) (pp. 1906-1917) https://doi.org/10.1007/s11095-005-7247-3
  228. Nahrendorf et al. (2009) 18F-4 V for PET CT Imaging of VCAM-1 Expression in Atherosclerosis 2(10) (pp. 1213-1222)
  229. Chan et al. (2010) Spatiotemporal controlled delivery of nanoparticles to injured vasculature 107(5) (pp. 2213-2218) https://doi.org/10.1073/pnas.0914585107
  230. Ehrhardt et al. (2004) Selectin-an emerging target for drug delivery 56(4) (pp. 527-549) https://doi.org/10.1016/j.addr.2003.10.029
  231. Dustin et al. (1986) Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1) 137(1) (pp. 245-254)
  232. Kang et al. (2011) Tunable physiologic interactions of adhesion molecules for inflamed cell-selective drug delivery 32(13) (pp. 3487-3498) https://doi.org/10.1016/j.biomaterials.2011.01.046
  233. Gottesman et al. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters 2(1) (pp. 48-58) https://doi.org/10.1038/nrc706
  234. Thomas and Coley (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein 10(2)
  235. Choi (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal 5(1) https://doi.org/10.1186/1475-2867-5-30
  236. Gillet, J.-P., Gottesman, M.M.: Mechanisms of multidrug resistance in cancer. Multi-drug Resistance in Cancer. Methods Mol. Biol. 47–76 (2010)
  237. Jain (1987) Transport of molecules in the tumor interstitium: a review 47(12) (pp. 3039-3051)
  238. Zahreddine, H., Borden, K.L.: Mechanisms and insights into drug resistance in cancer. Frontiers in Pharmacology
  239. 4
  240. (28.10), 3389 (2013)
  241. Sampath et al. (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial 107(6) (pp. 2517-2524) https://doi.org/10.1182/blood-2005-08-3351
  242. Michael and Doherty (2005) Tumoral drug metabolism: overview and its implications for cancer therapy 23(1) (pp. 205-229) https://doi.org/10.1200/JCO.2005.02.120
  243. Demant et al. (1990) A model for computer simulation of P-glycoprotein and transmembrane ΔpH-mediated anthracycline transport in multidrug-resistant tumor cells. Biochimica et Biophysica Acta (BBA)-Molecular 1055(2) (pp. 117-125)
  244. Ullah (2008) Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy 9(1) (pp. 1-6)
  245. Gottesman (2002) Mechanisms of cancer drug resistance 53(1) (pp. 615-627) https://doi.org/10.1146/annurev.med.53.082901.103929
  246. Leonard et al. (2003) The role of ABC transporters in clinical practice 8(5) (pp. 411-424) https://doi.org/10.1634/theoncologist.8-5-411
  247. Liu (2009) Mechanisms of chemotherapeutic drug resistance in cancer therapy: a quick review 48(3) (pp. 239-244) https://doi.org/10.1016/S1028-4559(09)60296-5
  248. van de Ven et al. (2009) ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer 86(5) (pp. 1075-1087) https://doi.org/10.1189/jlb.0309147
  249. Riordan et al. (1985) Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines 316(6031) (pp. 817-819) https://doi.org/10.1038/316817a0
  250. Doyle et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells 95(26) (pp. 15665-15670) https://doi.org/10.1073/pnas.95.26.15665
  251. Borst et al. (2000) A family of drug transporters: the multidrug resistance-associated proteins 92(16) (pp. 1295-1302) https://doi.org/10.1093/jnci/92.16.1295
  252. Juliano, R.L., Ling, V.: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta (BBA)-Biomembranes
  253. 455
  254. (1), 152–162 (1976)
  255. Ambudkar et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1 39(1) (pp. 361-398) https://doi.org/10.1146/annurev.pharmtox.39.1.361
  256. Dean et al. (2005) Tumour stem cells and drug resistance 5(4) (pp. 275-284) https://doi.org/10.1038/nrc1590
  257. Vinogradov and Wei (2012) Cancer stem cells and drug resistance: the potential of nanomedicine 7(4) (pp. 597-615) https://doi.org/10.2217/nnm.12.22
  258. Charafe-Jauffret et al. (2008) Cancer stem cells in breast: current opinion and future challenges 75(2) (pp. 75-84) https://doi.org/10.1159/000123845
  259. Ponti et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties 65(13) (pp. 5506-5511) https://doi.org/10.1158/0008-5472.CAN-05-0626
  260. Prince et al. (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma 104(3) (pp. 973-978) https://doi.org/10.1073/pnas.0610117104
  261. Clarke et al. (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells 66(19) (pp. 9339-9344) https://doi.org/10.1158/0008-5472.CAN-06-3126
  262. Dick (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell (pp. 730-737) https://doi.org/10.1038/nm0797-730
  263. Hotamisligil, G.k.S.: Inflammation and metabolic disorders. Nature
  264. 444
  265. (7121), 860–867 (2006)
  266. Facchini et al. (2001) Insulin resistance as a predictor of age-related diseases 86(8) (pp. 3574-3578) https://doi.org/10.1210/jcem.86.8.7763
  267. Loscher and Potschka (2005) Drug resistance in brain diseases and the role of drug efflux transporters 6(8) (pp. 591-602) https://doi.org/10.1038/nrn1728
  268. Doan et al. (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs 303(3) (pp. 1029-1037) https://doi.org/10.1124/jpet.102.039255
  269. Bartok and Firestein (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis 233(1) (pp. 233-255) https://doi.org/10.1111/j.0105-2896.2009.00859.x
  270. Morgan et al. (2003) Contribution of patient related differences to multidrug resistance in rheumatoid arthritis 62(1) (pp. 15-19) https://doi.org/10.1136/ard.62.1.15
  271. Sharma et al. (2015) Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes 13(1) https://doi.org/10.1186/s12951-015-0136-y
  272. Shaji, J., Patole, V.: Protein and peptide drug delivery: oral approaches. Indian J. Pharm. Sci. (2008)
  273. Bhumkar et al. (2007) Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin 24(8) (pp. 1415-1426) https://doi.org/10.1007/s11095-007-9257-9
  274. Kudva et al. (2014) Closed-loop artificial pancreas systems: physiological input to enhance next-generation devices 37(5) (pp. 1184-1190) https://doi.org/10.2337/dc13-2066
  275. Zhang et al. (2015) Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma (pp. 2089-2100) https://doi.org/10.2147/DDDT.S79592
  276. Brem et al. (1991) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas 74(3) (pp. 441-446) https://doi.org/10.3171/jns.1991.74.3.0441
  277. Grossman et al. (1992) The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers 76(4) (pp. 640-647) https://doi.org/10.3171/jns.1992.76.4.0640
  278. Ellington and Szostak (1990) In vitro selection of RNA molecules that bind specific ligands 346(6287) (pp. 818-822) https://doi.org/10.1038/346818a0
  279. Tuerk and Gold (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase 249(4968) (pp. 505-510) https://doi.org/10.1126/science.2200121
  280. Schneider et al. (1995) High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus 34(29) (pp. 9599-9610) https://doi.org/10.1021/bi00029a037
  281. Mosing et al. (2005) Capillary electrophoresis-SELEX selection of aptamers with affinity for HIV-1 reverse transcriptase 77(19) (pp. 6107-6112) https://doi.org/10.1021/ac050836q
  282. Chen et al. (2009) CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2 4(12) https://doi.org/10.1371/journal.pone.0008142
  283. Ng et al. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease 5(2) (pp. 123-132) https://doi.org/10.1038/nrd1955
  284. Farokhzad et al. (2004) Nanoparticle-aptamer bioconjugates a new approach for targeting prostate cancer cells 64(21) (pp. 7668-7672) https://doi.org/10.1158/0008-5472.CAN-04-2550
  285. Cerchia, L., Giangrande, P.H., McNamara, J.O., de Franciscis, V.: Cell-specific aptamers for targeted therapies. Nucleic Acid Peptide Aptamers Methods Protocols, 59–78 (2009)
  286. Cerchia and de Franciscis (2010) Targeting cancer cells with nucleic acid aptamers 28(10) (pp. 517-525) https://doi.org/10.1016/j.tibtech.2010.07.005
  287. Sefah et al. (2010) Development of DNA aptamers using Cell-SELEX 5(6) (pp. 1169-1185) https://doi.org/10.1038/nprot.2010.66
  288. Meng et al. (2010) Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line 4(8) (pp. 4539-4550) https://doi.org/10.1021/nn100690m
  289. Zhao and Feng (2015) Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents 10(14) (pp. 2199-2228) https://doi.org/10.2217/nnm.15.61
  290. Saul et al. (2006) A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers 114(3) (pp. 277-287) https://doi.org/10.1016/j.jconrel.2006.05.028
  291. Reardon et al. (2008) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme 17(8) (pp. 1225-1235) https://doi.org/10.1517/13543784.17.8.1225
  292. Duskey and Rice (2014) Nanoparticle ligand presentation for targeting solid tumors 15(5) (pp. 1345-1354) https://doi.org/10.1208/s12249-014-0143-6
  293. Gao et al. (2012) Nanotechnology applied to overcome tumor drug resistance 162(1) (pp. 45-55) https://doi.org/10.1016/j.jconrel.2012.05.051
  294. Chen et al. (2015) pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells
  295. Rao et al. (2015) Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells 9(6) (pp. 5725-5740) https://doi.org/10.1021/nn506928p
  296. Hu and Fu (2012) Targeting cancer stem cells: a new therapy to cure cancer patients 2(3) (pp. 340-356)